Pacira BioSciences, Inc. Common Stock (PCRX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCRX trades at $22.23 with a market cap of $882.97M and a P/E ratio of 140.38. PCRX moved -1.70% today. Year to date, PCRX is -8.79%; over the trailing twelve months it is -14.68%. Its 52-week range spans $13.89 to $27.64. Analyst consensus is buy with an average price target of $28.40. Rallies surfaces PCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pacira Unveils $200M Buyback, 2025 Revenue Hits $726.4M with 79.4% Margin: Pacira highlighted record 2025 revenue of $726.4 million with GAAP gross margin of 79.4% and 22% total shareholder return since launching its 5x30 strategy in January 2025. It reported Q1 revenue of $143.3M for EXPAREL (+5%) and $26.8M for ZILRETTA (+15%), unveiled a $200M repurchase plus EXPAREL exclusivity to 2030.
| Metric | Value |
|---|---|
| Price | $22.23 |
| Market Cap | $882.97M |
| P/E Ratio | 140.38 |
| EPS | $0.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.64 |
| 52-Week Low | $13.89 |
| Volume | 64.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $726.41M |
| Net Income | $7.03M |
| Gross Margin | 79.39% |
6 analysts cover PCRX: 0 strong buy, 3 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.40.